Stay up to date with notifications from The Independent

Notifications can be managed in browser preferences.

SKB to shed 800 jobs in shake-up

Roger Trapp
Thursday 08 July 1999 18:02 EDT
Comments

Your support helps us to tell the story

From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.

At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.

The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.

Your support makes all the difference.

TWO HUNDRED and forty jobs are to go at pharmaceutical company SmithKline Beecham's Worthing factory as part of plans to cut the worldwide workforce of 58,000 by 800.

The job cuts result from proposals to consolidate the company's antibiotic producingoperations into "global centres of excellence". Although the West Sussex plant will be one of these five key sites, it is losing the workers under a pounds 8.2m investment intended to make it more efficient.

The initiative - which is being driven by strong competition, lower prices and a general trend to reduce industry capacity - is itself part of a four-year worldwide restructuring of operations announced at the time of the company's annual results in February.

Jan Leschly, chief executive of the company, which reported pre-tax profits of pounds 1.7bn on turnover of just over pounds 8bn last year, said the chosen plants would provide "an efficient antibiotic supply network for the future". The priority, he added, would be to develop state-of-the-art facilities with the aim of ensuring customers receive top-quality products at competitive prices.

The company is planning to sell five other sites, spread between Spain, France, Mexico and the United States that are not seen as key to this plan.

Join our commenting forum

Join thought-provoking conversations, follow other Independent readers and see their replies

Comments

Thank you for registering

Please refresh the page or navigate to another page on the site to be automatically logged inPlease refresh your browser to be logged in